New Inhaled Antibiotic To Treat Respiratory Infections

https://www.europeanpharmaceuticalreview.com/news/67983/polyphor-antibiotic-murepavadin/

Polyphor launches the development of an inhaled antibiotic murepavadin

Polyphor Ltd has announced the development of an inhaled dosage form of its break­through antibiotic Murepavadin. Continue reading New Inhaled Antibiotic To Treat Respiratory Infections

New Pre-Clinical Data for Iclaprim

Motif Bio Presents New Pre-Clinical Data for Iclaprim at IDWeek 2017™

https://globenewswire.com/news-release/2017/10/06/1142163/0/en/Motif-Bio-Presents-New-Pre-Clinical-Data-for-Iclaprim-at-IDWeek-2017.html

1. Pre-Clinical Data Support the Potential Use of Iclaprim in the Treatment of Staphylococcus aureus Pneumonia in Cystic Continue reading New Pre-Clinical Data for Iclaprim

Fighting an old enemy in the battle against cystic fibrosis

http://msutoday.msu.edu/news/2017/fighting-an-old-enemy-in-the-battle-against-cystic-fibrosis/

Published: Aug. 29, 2017

Michael Maiden, a Michigan State University College of Osteopathic Medicine student and doctoral candidate in the Department of Microbiology and Molecular Genetics, was Continue reading Fighting an old enemy in the battle against cystic fibrosis

Phase Two Clinical Trials to treat NTM

http://www.nasdaq.com/press-release/ait-therapeutics-announces-enrollment-of-first-patient-into-its-nontm-abscessus-phase-2-trial-in-20170807-00641

AIT Therapeutics Announces Enrollment of First Patient into Its NO-NTM abscessus Phase 2 Trial in Nontuberculous Mycobacteria (NTM)

10 patients with Mycobacterium Abscessus Complex (MABSC) are expected to enroll in the trial Continue reading Phase Two Clinical Trials to treat NTM

News on new drug to treat B. Cepacia

https://cysticfibrosisnewstoday.com/2017/07/31/synspira-snsp113-may-be-game-changer-cf-cystic-fibrosis-drug-resistant-bacteria/

Originally published on Cystic Fibrosis Today Website 7/31/17
By Reid D’Amico

Synspira’s CF Therapy May Be Game-Changer for Drug-Resistant Bacteria

Chronic pulmonary infections are a hallmark of lung disease in patients with cystic fibrosis. Due to the variability in bacteria that can colonize the lung and Continue reading News on new drug to treat B. Cepacia

French Biotech Receives an Award to Develop a Novel Cystic Fibrosis Antibiotic

https://labiotech.eu/antabio-carb-x-cystic-fibrosis/

CARB-X has awarded $8.9M (€7.6M) to Antabio for the development of a new antibiotic against resistant Pseudomonas infections in cystic fibrosis patients.

Antabio is a French company developing new antibiotics to fight the rapidly Continue reading French Biotech Receives an Award to Develop a Novel Cystic Fibrosis Antibiotic

New Drug Improves Effectiveness of Antibiotics against Drug-resistant Bacteria

Synspira’s Novel Glycopolymer Improves Effectiveness of Antibiotics Against Drug-resistant Bacteria Associated with Cystic Fibrosis

Synspira, a privately held company developing a new class of inhaled glycopolymer-based therapeutics for the treatment of pulmonary disease, Continue reading New Drug Improves Effectiveness of Antibiotics against Drug-resistant Bacteria

New Drug to Help with Resistant Fungal Lung Infections

TGV-inhalonix, a New York drug development company behind ground-breaking Mul-1867 which gives hope to treating life-threatening, antibiotic-resistant bacterial lung infections in patients suffering from cystic fibrosis, announced that Mul-1867 has shown tremendous potential against clinical isolates of fungi from patients with cystic fibrosis and other severe lung infections. Continue reading New Drug to Help with Resistant Fungal Lung Infections